- The disease
- Central sleep apnea (CSA) and complex sleep apnea syndrome (CompSA) are breathing disorders in which the brain fails to send consistent signals to the muscles that control breathing during sleep. Unlike obstructive sleep apnea (OSA), where the airway is physically blocked, CSA and CompSA involve a failure of respiratory drive. These conditions can cause disrupted sleep, low blood oxygen levels, and are associated with heart failure and other cardiovascular conditions. They are distinct from OSA and generally require different ventilatory support strategies.
- What the asset is trying to do
- The AirCurve 11 is a bilevel positive airway pressure (BiPAP) device that delivers two distinct pressure levels: a higher pressure during inhalation and a lower pressure during exhalation. This pressure differential is intended to support breathing in patients whose respiratory drive is impaired or irregular, as occurs in CSA and CompSA. The device differs from standard continuous positive airway pressure (CPAP) devices, which deliver a single fixed pressure, by actively assisting each breath rather than simply maintaining airway patency. Some AirCurve 11 variants include adaptive servo-ventilation (ASV) or spontaneous-timed (ST) modes to respond to changes in breathing patterns in real time.
- Efficacy benchmarks in this setting
- For central and complex sleep apnea, approved bilevel and adaptive servo-ventilation devices have been evaluated in several studies. The SERVE-HF trial (Cowie et al, NEJM 2015) evaluated ASV in heart-failure patients with predominantly CSA and reported a reduction in the apnea-hypopnea index (AHI, a count of breathing interruptions per hour of sleep) with active treatment, but also observed increased cardiovascular mortality in that specific population. For CompSA specifically, published data show that a proportion of patients initially presenting with CompSA on CPAP see resolution of central events over time with continued CPAP use, though reported rates vary across studies. Early-stage or post-market figures for the AirCurve 11 in these settings are not statistically comparable to pivotal trial outcomes for approved predecessor devices.
- Commercial context
- The AirCurve 11 is a commercially approved medical device marketed by ResMed Inc. (NYSE/ASX: RMD) for bilevel positive airway pressure therapy. ResMed has disclosed the AirCurve 11 as part of its sleep and breathing solutions product portfolio. The US Food and Drug Administration (FDA) has cleared bilevel PAP devices for CSA and CompSA indications; the specific 510(k) or PMA clearance number for the AirCurve 11 is . No pipeline-stage regulatory designations are on file for this asset. The none of the clinical trials listed in the input data appear to be lead registration trials for the AirCurve 11 specifically in central or complex sleep apnea; those trials address OSA, stroke, COPD, and mask systems.